Assumed Vaccine Efficacy for Susceptibility (VES) for naïve and previously infected individuals, estimated from the overall efficacy found by the Sanofi-Pasteur phase III vaccine trial.
收藏数据链接：
官方服务：
资源简介：
Efficacies for naïve and previously infected individuals are calculated assuming a population that is 60% antibody positive and that efficacy in seropositive individuals is twice that of seronegatives.
创建时间：
2016-09-28
